|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Blood clotting
|
 |
|
Title:
|
 |
Crystal structure of the endothelial protein c receptor with phospholipid in the groove in complex with gla domain of pr
|
|
Structure:
|
 |
Endothelial protein c receptor. Chain: a, b. Fragment: extracellular domain. Synonym: endothelial cell protein c receptor, activated pro receptor, apc receptor. Engineered: yes. Vitamin-k dependent protein c. Chain: c, d. Fragment: protein c gla domain.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: cricetulus griseus. Expression_system_taxid: 10029. Other_details: cleavage happened during crystallization and crystal contains only the n-terminal domain (gla domain) of c.
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
1.60Å
|
R-factor:
|
0.189
|
R-free:
|
0.222
|
|
|
Authors:
|
 |
V.Oganesyan,N.Oganesyan,S.Terzyan,Q.Dongfeng,Z.Dauter,N.L.Es C.T.Esmon
|
Key ref:
|
 |
V.Oganesyan
et al.
(2002).
The crystal structure of the endothelial protein C receptor and a bound phospholipid.
J Biol Chem,
277,
24851-24854.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
13-May-02
|
Release date:
|
19-Jun-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains C, D:
E.C.3.4.21.69
- Protein C (activated).
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Degradation of blood coagulation factors Va and VIIIa.
|
 |
 |
 |
 |
 |
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
3 terms
|
 |
|
Biological process
|
immune response
|
2 terms
|
 |
|
Biochemical function
|
calcium ion binding
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
277:24851-24854
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
The crystal structure of the endothelial protein C receptor and a bound phospholipid.
|
|
V.Oganesyan,
N.Oganesyan,
S.Terzyan,
D.Qu,
Z.Dauter,
N.L.Esmon,
C.T.Esmon.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The endothelial cell protein C receptor (EPCR) shares approximately 20% sequence
identity with the major histocompatibility complex class 1/CD1 family of
molecules, accelerates the thrombin-thrombomodulin-dependent generation of
activated protein C, a natural anticoagulant, binds to activated neutrophils,
and can undergo translocation from the plasma membrane to the nucleus. Blocking
protein C/activated protein C binding to the receptor inhibits not only protein
C activation but the ability of the host to respond appropriately to bacterial
challenge, exacerbating both the coagulant and inflammatory responses. To
understand how EPCR accomplishes these multiple tasks, we solved the crystal
structure of EPCR alone and in complex with the phospholipid binding domain of
protein C. The structures were strikingly similar to CD1d. A tightly bound
phospholipid resides in the groove typically involved in antigen presentation.
The protein C binding site is outside this conserved groove and is distal from
the membrane-spanning domain. Extraction of the lipid resulted in loss of
protein C binding, which could be restored by lipid reconstitution. CD1d
augments the immune response by presenting glycolipid antigens. The EPCR
structure is a model for how CD1d binds lipids and further suggests additional
potential functions for EPCR in immune regulation, possibly including the
anti-phospholipid syndrome.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. The rsEPCR molecule with a portion of the protein
C Gla domain and a lipid molecule. In EPCR (yellow ribbon), two
-helices
and an eight-stranded -sheet
create a groove that is filled with phospholipid (the
space-filling balls in the center). Binding of Ca^2+ ions
(magenta spheres) to the protein C Gla domain (green ribbon)
exposes the N-terminal loop,
which in the absence of EPCR interacts with the phospholipid
surfaces on the membrane. There do not appear to be direct
interactions between the protein C Gla domain and the lipid
molecule located in the groove of rsEPCR. The model of the
complex consists of residues 7-177 of rsEPCR and the first 33
residues of the protein C Gla domain (25, 26).
|
 |
Figure 4.
Fig. 4. The amino acids participating in the interactions
between the Gla domain of protein C and rsEPCR. The yellow
portion is the interacting region of rsEPCR, the green portion
is the interacting region of the protein C Gla domain, and the
magenta balls represent the bound Ca^2+ ions. The lipid molecule
is shown in black (25, 26).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2002,
277,
24851-24854)
copyright 2002.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.R.Rezaie
(2010).
Regulation of the protein C anticoagulant and antiinflammatory pathways.
|
| |
Curr Med Chem, 17,
2059-2069.
|
 |
|
|
|
|
 |
C.S.Hee,
S.Gao,
B.Loll,
M.M.Miller,
B.Uchanska-Ziegler,
O.Daumke,
and
A.Ziegler
(2010).
Structure of a classical MHC class I molecule that binds "non-classical" ligands.
|
| |
PLoS Biol, 8,
e1000557.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.T.Esmon
(2010).
The discovery of the endothelial cell protein C receptor.
|
| |
J Thromb Haemost, 8,
2-5.
|
 |
|
|
|
|
 |
M.Levi,
and
T.van der Poll
(2010).
Inflammation and coagulation.
|
| |
Crit Care Med, 38,
S26-S34.
|
 |
|
|
|
|
 |
P.P.Sarangi,
H.W.Lee,
and
M.Kim
(2010).
Activated protein C action in inflammation.
|
| |
Br J Haematol, 148,
817-833.
|
 |
|
|
|
|
 |
Y.Z.Ohkubo,
J.H.Morrissey,
and
E.Tajkhorshid
(2010).
Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor.
|
| |
J Thromb Haemost, 8,
1044-1053.
|
 |
|
|
|
|
 |
F.Chiappori,
P.D'Ursi,
I.Merelli,
L.Milanesi,
and
E.Rovida
(2009).
In silico saturation mutagenesis and docking screening for the analysis of protein-ligand interaction: the Endothelial Protein C Receptor case study.
|
| |
BMC Bioinformatics, 10,
S3.
|
 |
|
|
|
|
 |
J.H.Finigan,
A.Boueiz,
E.Wilkinson,
R.Damico,
J.Skirball,
H.H.Pae,
M.Damarla,
E.Hasan,
D.B.Pearse,
S.P.Reddy,
D.N.Grigoryev,
C.Cheadle,
C.T.Esmon,
J.G.Garcia,
and
P.M.Hassoun
(2009).
Activated protein C protects against ventilator-induced pulmonary capillary leak.
|
| |
Am J Physiol Lung Cell Mol Physiol, 296,
L1002-L1011.
|
 |
|
|
|
|
 |
J.Wang,
and
J.Li
(2009).
Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion.
|
| |
Am J Transl Res, 1,
381-392.
|
 |
|
|
|
|
 |
J.Xu,
Y.Ji,
X.Zhang,
M.Drake,
and
C.T.Esmon
(2009).
Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock.
|
| |
J Thromb Haemost, 7,
851-856.
|
 |
|
|
|
|
 |
L.Altaweel,
D.Sweeney,
X.Cui,
A.Barochia,
C.Natanson,
and
P.Qeichacker
(2009).
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.
|
| |
Biologics, 3,
391-406.
|
 |
|
|
|
|
 |
L.O.Mosnier,
A.Zampolli,
E.J.Kerschen,
R.A.Schuepbach,
Y.Banerjee,
J.A.Fernández,
X.V.Yang,
M.Riewald,
H.Weiler,
Z.M.Ruggeri,
and
J.H.Griffin
(2009).
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.
|
| |
Blood, 113,
5970-5978.
|
 |
|
|
|
|
 |
M.Pérez-Casal,
C.Downey,
B.Cutillas-Moreno,
M.Zuzel,
K.Fukudome,
and
C.H.Toh
(2009).
Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects.
|
| |
Haematologica, 94,
387-394.
|
 |
|
|
|
|
 |
Q.Zhang,
H.H.Petersen,
H.Ostergaard,
W.Ruf,
and
A.J.Olson
(2009).
Molecular dynamics simulations and functional characterization of the interactions of the PAR2 ectodomain with factor VIIa.
|
| |
Proteins, 77,
559-569.
|
 |
|
|
|
|
 |
S.Koarada,
N.Tsuneyoshi,
Y.Haruta,
Y.Tada,
M.Mitamura,
H.Inoue,
A.Ohta,
K.Fukudome,
and
K.Nagasawa
(2009).
Effect of disease activity and corticosteroids on serum levels of soluble endothelial cell protein C receptor in patients with systemic lupus erythematosus.
|
| |
Mod Rheumatol, 19,
173-179.
|
 |
|
|
|
|
 |
X.V.Yang,
Y.Banerjee,
J.A.Fernández,
H.Deguchi,
X.Xu,
L.O.Mosnier,
R.T.Urbanus,
P.G.de Groot,
T.C.White-Adams,
O.J.McCarty,
and
J.H.Griffin
(2009).
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells.
|
| |
Proc Natl Acad Sci U S A, 106,
274-279.
|
 |
|
|
|
|
 |
E.E.Winger,
and
J.L.Reed
(2008).
Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion.
|
| |
Am J Reprod Immunol, 60,
8.
|
 |
|
|
|
|
 |
J.Diao,
and
E.Tajkhorshid
(2008).
Indirect role of Ca2+ in the assembly of extracellular matrix proteins.
|
| |
Biophys J, 95,
120-127.
|
 |
|
|
|
|
 |
J.S.Bae,
L.Yang,
and
A.R.Rezaie
(2008).
Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells.
|
| |
J Thromb Haemost, 6,
954-961.
|
 |
|
|
|
|
 |
R.E.Saunders,
and
S.J.Perkins
(2008).
CoagMDB: a database analysis of missense mutations within four conserved domains in five vitamin K-dependent coagulation serine proteases using a text-mining tool.
|
| |
Hum Mutat, 29,
333-344.
|
 |
|
|
|
|
 |
S.H.Qureshi,
L.Yang,
C.Manithody,
J.S.Bae,
and
A.R.Rezaie
(2008).
Functional properties and active-site topographies of factor X Gla- and prothrombin Gla-domain chimeras of activated protein C.
|
| |
Biochim Biophys Acta, 1780,
1080-1086.
|
 |
|
|
|
|
 |
T.Dutt,
and
C.H.Toh
(2008).
The Yin-Yang of thrombin and activated protein C.
|
| |
Br J Haematol, 140,
505-515.
|
 |
|
|
|
|
 |
D.Qu,
Y.Wang,
N.L.Esmon,
and
C.T.Esmon
(2007).
Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17.
|
| |
J Thromb Haemost, 5,
395-402.
|
 |
|
|
|
|
 |
J.H.Griffin,
J.A.Fernández,
A.J.Gale,
and
L.O.Mosnier
(2007).
Activated protein C.
|
| |
J Thromb Haemost, 5,
73-80.
|
 |
|
|
|
|
 |
J.López-Sagaseta,
R.Montes,
C.Puy,
N.Díez,
K.Fukudome,
and
J.Hermida
(2007).
Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity.
|
| |
J Thromb Haemost, 5,
1817-1824.
|
 |
|
|
|
|
 |
J.S.Bae,
L.Yang,
and
A.R.Rezaie
(2007).
Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells.
|
| |
Proc Natl Acad Sci U S A, 104,
2867-2872.
|
 |
|
|
|
|
 |
J.T.Crawley
(2007).
Multiple roles of the endothelial cell protein C receptor.
|
| |
J Thromb Haemost, 5,
1813-1816.
|
 |
|
|
|
|
 |
M.Levi,
and
T.van der Poll
(2007).
Recombinant human activated protein C: current insights into its mechanism of action.
|
| |
Crit Care, 11,
S3.
|
 |
|
|
|
|
 |
M.Xue,
L.March,
P.N.Sambrook,
K.Fukudome,
and
C.J.Jackson
(2007).
Endothelial protein C receptor is overexpressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes.
|
| |
Ann Rheum Dis, 66,
1574-1580.
|
 |
|
|
|
|
 |
P.D'Ursi,
F.Marino,
A.Caprera,
L.Milanesi,
E.M.Faioni,
and
E.Rovida
(2007).
ProCMD: a database and 3D web resource for protein C mutants.
|
| |
BMC Bioinformatics, 8,
S11.
|
 |
|
|
|
|
 |
A.B.Balazs,
A.J.Fabian,
C.T.Esmon,
and
R.C.Mulligan
(2006).
Endothelial protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow.
|
| |
Blood, 107,
2317-2321.
|
 |
|
|
|
|
 |
C.T.Esmon
(2006).
The endothelial protein C receptor.
|
| |
Curr Opin Hematol, 13,
382-385.
|
 |
|
|
|
|
 |
D.Qu,
Y.Wang,
Y.Song,
N.L.Esmon,
and
C.T.Esmon
(2006).
The Ser219-->Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype.
|
| |
J Thromb Haemost, 4,
229-235.
|
 |
|
|
|
|
 |
C.T.Esmon
(2005).
The interactions between inflammation and coagulation.
|
| |
Br J Haematol, 131,
417-430.
|
 |
|
|
|
|
 |
J.Klein,
and
N.Nikolaidis
(2005).
The descent of the antibody-based immune system by gradual evolution.
|
| |
Proc Natl Acad Sci U S A, 102,
169-174.
|
 |
|
|
|
|
 |
K.Hansson,
and
J.Stenflo
(2005).
Post-translational modifications in proteins involved in blood coagulation.
|
| |
J Thromb Haemost, 3,
2633-2648.
|
 |
|
|
|
|
 |
M.Xue,
D.Campbell,
P.N.Sambrook,
K.Fukudome,
and
C.J.Jackson
(2005).
Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C.
|
| |
J Invest Dermatol, 125,
1279-1285.
|
 |
|
|
|
|
 |
R.J.Preston,
A.Villegas-Mendez,
Y.H.Sun,
J.Hermida,
P.Simioni,
H.Philippou,
B.Dahlbäck,
and
D.A.Lane
(2005).
Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation.
|
| |
FEBS J, 272,
97.
|
 |
|
|
|
|
 |
R.Olson,
K.E.Huey-Tubman,
C.Dulac,
and
P.J.Bjorkman
(2005).
Structure of a pheromone receptor-associated MHC molecule with an open and empty groove.
|
| |
PLoS Biol, 3,
e257.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Maruoka,
H.Tanabe,
M.Chiba,
and
M.Kasahara
(2005).
Chicken CD1 genes are located in the MHC: CD1 and endothelial protein C receptor genes constitute a distinct subfamily of class-I-like genes that predates the emergence of mammals.
|
| |
Immunogenetics, 57,
590-600.
|
 |
|
|
|
|
 |
W.Li,
X.Zheng,
J.M.Gu,
G.L.Ferrell,
M.Brady,
N.L.Esmon,
and
C.T.Esmon
(2005).
Extraembryonic expression of EPCR is essential for embryonic viability.
|
| |
Blood, 106,
2716-2722.
|
 |
|
|
|
|
 |
B.Dahlbäck
(2004).
Progress in the understanding of the protein C anticoagulant pathway.
|
| |
Int J Hematol, 79,
109-116.
|
 |
|
|
|
|
 |
C.T.Esmon
(2004).
Structure and functions of the endothelial cell protein C receptor.
|
| |
Crit Care Med, 32,
S298-S301.
|
 |
|
|
|
|
 |
C.T.Esmon
(2004).
Interactions between the innate immune and blood coagulation systems.
|
| |
Trends Immunol, 25,
536-542.
|
 |
|
|
|
|
 |
E.M.Faioni,
S.Ferrero,
G.Fontana,
U.Gianelli,
M.M.Ciulla,
M.Vecchi,
S.Saibeni,
E.Biguzzi,
N.Cordani,
F.Franchi,
S.Bosari,
and
M.Cattaneo
(2004).
Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease.
|
| |
Crit Care Med, 32,
S266-S270.
|
 |
|
|
|
|
 |
M.Haley,
X.Cui,
P.C.Minneci,
K.J.Deans,
C.Natanson,
and
P.Q.Eichacker
(2004).
Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness.
|
| |
Curr Opin Infect Dis, 17,
205-211.
|
 |
|
|
|
|
 |
A.R.Rezaie,
and
L.Yang
(2003).
Thrombomodulin allosterically modulates the activity of the anticoagulant thrombin.
|
| |
Proc Natl Acad Sci U S A, 100,
12051-12056.
|
 |
|
|
|
|
 |
B.Dahlbäck,
and
B.O.Villoutreix
(2003).
Molecular recognition in the protein C anticoagulant pathway.
|
| |
J Thromb Haemost, 1,
1525-1534.
|
 |
|
|
|
|
 |
C.T.Esmon
(2003).
Inflammation and thrombosis.
|
| |
J Thromb Haemost, 1,
1343-1348.
|
 |
|
|
|
|
 |
D.Marsh
(2003).
Lipid-binding proteins: structure of the phospholipid ligands.
|
| |
Protein Sci, 12,
2109-2117.
|
 |
|
|
|
|
 |
M.Riewald,
and
W.Ruf
(2003).
Science review: role of coagulation protease cascades in sepsis.
|
| |
Crit Care, 7,
123-129.
|
 |
|
|
|
|
 |
S.A.Brown,
L.M.Aledort,
and
C.A.Lee
(2003).
Molecular challenges and viral diseases.
|
| |
Haemophilia, 9,
727-737.
|
 |
|
|
|
|
 |
C.T.Esmon
(2002).
New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins.
|
| |
J Exp Med, 196,
561-564.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|